BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mazzocchi G, Malendowicz LK, Aragona F, Rebuffat P, Gottardo L, Nussdorfer GG. Human Pheochromocytomas Express Orexin Receptor Type 2 Gene and Display an in Vitro Secretory Response to Orexins A and B. The Journal of Clinical Endocrinology & Metabolism 2001;86:4818-21. [DOI: 10.1210/jcem.86.10.7929] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Couvineau A, Dayot S, Nicole P, Gratio V, Rebours V, Couvelard A, Voisin T. The Anti-tumoral Properties of Orexin/Hypocretin Hypothalamic Neuropeptides: An Unexpected Therapeutic Role. Front Endocrinol (Lausanne) 2018;9:573. [PMID: 30319552 DOI: 10.3389/fendo.2018.00573] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
2 Wenzel J, Grabinski N, Knopp CA, Dendorfer A, Ramanjaneya M, Randeva HS, Ehrhart-Bornstein M, Dominiak P, Jöhren O. Hypocretin/orexin increases the expression of steroidogenic enzymes in human adrenocortical NCI H295R cells. Am J Physiol Regul Integr Comp Physiol 2009;297:R1601-9. [PMID: 19793950 DOI: 10.1152/ajpregu.91034.2008] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
3 Yang B, Samson WK, Ferguson AV. Excitatory effects of orexin-A on nucleus tractus solitarius neurons are mediated by phospholipase C and protein kinase C. J Neurosci 2003;23:6215-22. [PMID: 12867505 [PMID: 12867505 DOI: 10.1523/jneurosci.23-15-06215.2003] [Cited by in Crossref: 67] [Article Influence: 3.5] [Reference Citation Analysis]
4 Kukkonen JP. Physiology of the orexinergic/hypocretinergic system: a revisit in 2012. Am J Physiol Cell Physiol 2013;304:C2-32. [PMID: 23034387 DOI: 10.1152/ajpcell.00227.2012] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 9.3] [Reference Citation Analysis]
5 Larsson KP, Akerman KE, Magga J, Uotila S, Kukkonen JP, Näsman J, Herzig KH. The STC-1 cells express functional orexin-A receptors coupled to CCK release. Biochem Biophys Res Commun 2003;309:209-16. [PMID: 12943684 DOI: 10.1016/s0006-291x(03)01563-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
6 Kukkonen JP. Orexin/Hypocretin Signaling. Curr Top Behav Neurosci 2017;33:17-50. [PMID: 27909990 DOI: 10.1007/7854_2016_49] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
7 Kukkonen JP, Leonard CS. Orexin/hypocretin receptor signalling cascades. Br J Pharmacol 2014;171:314-31. [PMID: 23902572 DOI: 10.1111/bph.12324] [Cited by in Crossref: 104] [Cited by in F6Publishing: 91] [Article Influence: 13.0] [Reference Citation Analysis]
8 Bernard R, Lydic R, Baghdoyan HA. Hypocretin-1 causes G protein activation and increases ACh release in rat pons. Eur J Neurosci 2003;18:1775-85. [PMID: 14622212 DOI: 10.1046/j.1460-9568.2003.02905.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
9 Sokołowska P, Urbańska A, Biegańska K, Wagner W, Ciszewski W, Namiecińska M, Zawilska JB. Orexins protect neuronal cell cultures against hypoxic stress: an involvement of Akt signaling. J Mol Neurosci 2014;52:48-55. [PMID: 24243084 DOI: 10.1007/s12031-013-0165-7] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
10 Zheng C, Deng QQ, Liu LL, Wang MY, Zhang G, Sheng WL, Weng SJ, Yang XL, Zhong YM. Orexin-A differentially modulates AMPA-preferring responses of ganglion cells and amacrine cells in rat retina. Neuropharmacology 2015;93:80-93. [PMID: 25656479 DOI: 10.1016/j.neuropharm.2015.01.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
11 Spinazzi R, Rucinski M, Neri G, Malendowicz LK, Nussdorfer GG. Preproorexin and orexin receptors are expressed in cortisol-secreting adrenocortical adenomas, and orexins stimulate in vitro cortisol secretion and growth of tumor cells. J Clin Endocrinol Metab 2005;90:3544-9. [PMID: 15797953 DOI: 10.1210/jc.2004-2385] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 2.3] [Reference Citation Analysis]
12 Couvineau A, Voisin T, Nicole P, Gratio V, Blais A. Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions. World J Gastroenterol 2021; 27(44): 7582-7596 [PMID: 34908800 DOI: 10.3748/wjg.v27.i44.7582] [Reference Citation Analysis]
13 Fernø J, Señarís R, Diéguez C, Tena-Sempere M, López M. Orexins (hypocretins) and energy balance: More than feeding. Mol Cell Endocrinol 2015;418 Pt 1:17-26. [PMID: 26213323 DOI: 10.1016/j.mce.2015.07.022] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
14 Burdakov D, Liss B, Ashcroft FM. Orexin excites GABAergic neurons of the arcuate nucleus by activating the sodium--calcium exchanger. J Neurosci 2003;23:4951-7. [PMID: 12832517 [PMID: 12832517 DOI: 10.1523/jneurosci.23-12-04951.2003] [Cited by in Crossref: 113] [Article Influence: 5.9] [Reference Citation Analysis]
15 Graybill NL, Weissig V. A review of orexin's unprecedented potential as a novel, highly-specific treatment for various localized and metastatic cancers. SAGE Open Med 2017;5:2050312117735774. [PMID: 29147564 DOI: 10.1177/2050312117735774] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
16 Heinonen MV, Purhonen AK, Mäkelä KA, Herzig KH. Functions of orexins in peripheral tissues. Acta Physiol (Oxf) 2008;192:471-85. [PMID: 18294339 DOI: 10.1111/j.1748-1716.2008.01836.x] [Cited by in Crossref: 125] [Cited by in F6Publishing: 115] [Article Influence: 8.9] [Reference Citation Analysis]
17 Kenakin T. Biased agonism. F1000 Biol Rep 2009;1:87. [PMID: 20948603 DOI: 10.3410/B1-87] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
18 Xu R, Wang Q, Yan M, Hernandez M, Gong C, Boon WC, Murata Y, Ueta Y, Chen C. Orexin-A augments voltage-gated Ca2+ currents and synergistically increases growth hormone (GH) secretion with GH-releasing hormone in primary cultured ovine somatotropes. Endocrinology 2002;143:4609-19. [PMID: 12446588 DOI: 10.1210/en.2002-220506] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 1.5] [Reference Citation Analysis]
19 Kenakin T. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci 2007;28:407-15. [PMID: 17629960 DOI: 10.1016/j.tips.2007.06.009] [Cited by in Crossref: 167] [Cited by in F6Publishing: 155] [Article Influence: 11.1] [Reference Citation Analysis]
20 Alain C, Pascal N, Valérie G, Thierry V. Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target. Molecules 2021;26:4849. [PMID: 34443437 DOI: 10.3390/molecules26164849] [Reference Citation Analysis]
21 Kawada Y, Ueno S, Asayama K, Tsutsui M, Utsunomiya K, Toyohira Y, Morisada N, Tanaka K, Shirahata A, Yanagihara N. Stimulation of catecholamine synthesis by orexin-A in bovine adrenal medullary cells through orexin receptor 1. Biochem Pharmacol. 2003;66:141-147. [PMID: 12818374 DOI: 10.1016/S0006-2952(03)00236-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
22 Kenakin T. Collateral efficacy as a pharmacological problem applied to new drug discovery. Expert Opinion on Drug Discovery 2006;1:635-52. [DOI: 10.1517/17460441.1.7.635] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
23 Wang C, Moseley CK, Carlin SM, Wilson CM, Neelamegam R, Hooker JM. Radiosynthesis and evaluation of [11C]EMPA as a potential PET tracer for orexin 2 receptors. Bioorg Med Chem Lett 2013;23:3389-92. [PMID: 23601709 DOI: 10.1016/j.bmcl.2013.03.079] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
24 Leonard CS, Kukkonen JP. Orexin/hypocretin receptor signalling: a functional perspective. Br J Pharmacol 2014;171:294-313. [PMID: 23848055 DOI: 10.1111/bph.12296] [Cited by in Crossref: 82] [Cited by in F6Publishing: 84] [Article Influence: 10.3] [Reference Citation Analysis]
25 Chen C, Xu R. The In Vitro Regulation of Growth Hormone Secretion by Orexins. ENDO 2003;22:57-66. [DOI: 10.1385/endo:22:1:57] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
26 Holmqvist T, Johansson L, Ostman M, Ammoun S, Akerman KE, Kukkonen JP. OX1 orexin receptors couple to adenylyl cyclase regulation via multiple mechanisms. J Biol Chem 2005;280:6570-9. [PMID: 15611118 DOI: 10.1074/jbc.M407397200] [Cited by in Crossref: 89] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
27 James MH, Campbell EJ, Dayas CV. Role of the Orexin/Hypocretin System in Stress-Related Psychiatric Disorders. Curr Top Behav Neurosci 2017;33:197-219. [PMID: 28083790 DOI: 10.1007/7854_2016_56] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 11.0] [Reference Citation Analysis]
28 Kukkonen JP, Holmqvist T, Ammoun S, Åkerman KEO. Functions of the orexinergic/hypocretinergic system. American Journal of Physiology-Cell Physiology 2002;283:C1567-91. [DOI: 10.1152/ajpcell.00055.2002] [Cited by in Crossref: 200] [Cited by in F6Publishing: 188] [Article Influence: 10.0] [Reference Citation Analysis]
29 Kukkonen JP. Lipid signaling cascades of orexin/hypocretin receptors. Biochimie 2014;96:158-65. [PMID: 23810911 DOI: 10.1016/j.biochi.2013.06.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]